Search | Clinical Trials Finder

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Coronary Artery Disease
Interventions: Maharishi Amrit Kalash, vitamin C + E, Inert Placebo Capsule; Dietary Supplement · Other
Lead sponsor: Maharishi International University; Other
Eligibility: 55 Years to 90 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Fairfield, Iowa

Conditions: Resectable Non-small Cell Lung Cancer
Interventions: Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more

Conditions: Infant, Newborn, Hypoxia-Ischemia, Brain
Interventions: Induced hypothermia, Control; Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 6 Hours
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Dyslipidemia
Interventions: LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 38
States / cities: Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more

Conditions: Diabetes Mellitus Type 2
Interventions: BMS-986036, Placebo (Matching with BMS-986036); Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more

Conditions: Healthy Volunteers
Interventions: BMS-985521, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Immunodeficiency Virus Type 1, Human
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more

Conditions: Pharmacokinetics and Safety of Elevated Doses
Interventions: teduglutide, tedguglutide; Drug
Lead sponsor: Shire; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Lancaster, California • Ventura, California • Walnut Creek, California + 9 more

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more

Conditions: Hepatitis C Infection, Thrombocytopenia
Interventions: romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pharmacokinetics
Interventions: Liposomal vitamin C, 1 gram, Liposomal vitamin C, 2 grams, Liposomal vitamin C, 5 grams, Placebo; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Obesity, Overweight
Interventions: LY4174794, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Chronic Hepatitis C
Interventions: ANZ-521, Placebo; Drug
Lead sponsor: Anza Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Anaheim, California • San Antonio, Texas

Conditions: Normal Physiology
Interventions: Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: GS-0151, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Anniston, Alabama • La Jolla, California • Palo Alto, California + 15 more

Conditions: Obstructive Sleep Apnea
Interventions: AD109 dose1- A, AD109 dose2- B, Placebo- C; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Diego, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Dermatitis Atopic
Interventions: Lunsekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Encino, California • Sacramento, California • Thousand Oaks, California + 19 more

Conditions: Alopecia Areata
Interventions: LAD603, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lateral Canthal Lines
Interventions: RT001, Placebo; Drug · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more

Conditions: Vasodilation, Arterial Stiffness
Interventions: Acetylcholine, Sodium Nitroprusside, Ascorbic Acid; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Acute Myeloid Leukemia
Interventions: Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more

Search by objective public record fields.

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Evaluation of an Ayurvedic Herbal Compound Compared to Vitamins C+E and Placebo on Vascular Function in High-Risk Subjects

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Whole-Body Cooling for Birth Asphyxia in Term Infants

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Antioxidant Bioavailability

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

Study of GS-0151 in Participants With Rheumatoid Arthritis

AD109 Dose Finding in Mild to Moderate OSA

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

A Study of LAD603 in Adults With Alopecia Areata

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Targeting ER Stress in Vascular Dysfunction

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission